The UK myotonic dystrophy patient registry: facilitating and accelerating clinical research by Wood, Libby et al.
ORIGINAL COMMUNICATION
The UK Myotonic Dystrophy Patient Registry: facilitating
and accelerating clinical research
Libby Wood1 • Isabell Cordts1,2 • Antonio Atalaia1 • Chiara Marini-Bettolo1 •
Paul Maddison3 • Margaret Phillips4 • Mark Roberts5 • Mark Rogers6 •
Simon Hammans7 • Volker Straub1 • Richard Petty8 • Richard Orrell9 •
Darren G. Monckton10 • Nikoletta Nikolenko1 • Aura Cecilia Jimenez-Moreno1 •
Rachel Thompson1 • David Hilton-Jones11 • Chris Turner12 • Hanns Lochmu¨ller1
Received: 5 January 2017 / Revised: 3 April 2017 / Accepted: 3 April 2017
 The Author(s) 2017. This article is an open access publication
Abstract Myotonic dystrophy type 1 (DM1) is the most
frequent muscular dystrophy worldwide with complex,
multi-systemic, and progressively worsening symptoms.
There is currently no treatment for this inherited disorder
and research can be challenging due to the rarity and
variability of the disease. The UK Myotonic Dystrophy
Patient Registry is a patient self-enrolling online database
collecting clinical and genetic information. For this cross-
sectional ‘‘snapshot’’ analysis, 556 patients with a con-
firmed diagnosis of DM1 registered between May 2012
and July 2016 were included. An almost even distribution
was seen between genders and a broad range of ages was
present from 8 months to 78 years, with the largest
proportion between 30 and 59 years. The two most fre-
quent symptoms were fatigue and myotonia, reported by
79 and 78% of patients, respectively. The severity of
myotonia correlated with the severity of fatigue as well as
mobility impairment, and dysphagia occurred mostly in
patients also reporting myotonia. Men reported signifi-
cantly more frequent severe myotonia, whereas severe
fatigue was more frequently reported by women. Cardiac
abnormalities were diagnosed in 48% of patients and
more than one-third of them needed a cardiac implant.
Fifteen percent of patients used a non-invasive ventilation
and cataracts were removed in 26% of patients, 65% of
which before the age of 50 years. The registry’s primary
aim was to facilitate and accelerate clinical research.
However, these data also allow us to formulate questions
for hypothesis-driven research that may lead to
improvements in care and treatment.
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Introduction
In most populations myotonic dystrophy is the most com-
mon muscular dystrophy. With an estimated prevalence of
10 per 100,000 people affected in European populations
[1, 2], we estimate upwards of 6500 people to be affected
in the UK, the majority with myotonic dystrophy type 1
(DM1). DM1 is one of the most variable human diseases
with complex, multi-systemic, and progressively worsen-
ing symptoms. The main muscle symptoms are distal to
proximal muscle weakness and myotonia. Pulmonary and
cardiac functions are also impaired with sudden death from
cardiac complications being a significant cause of fatality
[3]. Other prominent clinical features are cataracts, cog-
nitive and intellectual deficits, endocrine abnormalities,
and gastrointestinal related symptoms [4]. Excessive day-
time sleepiness and psychiatric symptoms might lead to
restricted social participation and quality of life can be
seriously impaired [5–7]. Some gender differences for
phenotype severity in DM1 have been suggested recently
in large French cohort study [8]. There is currently no
curative treatment for this complex condition.
DM1 is the result of a triplet CTG repeat expansion in
the 30-untranslated region of the dystrophia myotonica-
protein kinase (DMPK) gene on chromosome 19 [9–11].
The diverse range of symptoms is thought to occur due to
the ongoing expansion of the repeat throughout life in
different organs, which results in aberrant splicing in a
large number of transcripts [12, 13]. The better under-
standing of the underlying molecular pathology has led to
the design of new targeted treatment approaches such as
antisense oligonucleotide therapies [14–16] and has
increased commercial and academic interest in DM1 over
recent years. As scientific and clinical progress is made, it
is paramount to prepare this diverse population for clinical
trials and patient registries can be a useful and important
tool in helping to overcome many of the hurdles faced by
rare diseases. Notably they can be utilised for planning and
recruitment of clinical trials [17–21].
The UK Myotonic Dystrophy Patient Registry was
established in May 2012 with support from the Muscular
Dystrophy UK (MDUK) and the Myotonic Dystrophy
Support Group (MDSG), assisted by the TREAT-NMD
Alliance (www.treat-nmd.eu). The registry is coordinated
from the John Walton Muscular Dystrophy Research
Centre at Newcastle University and collects clinical and
genetic information about both DM1 and myotonic dys-
trophy type 2 (DM2). A total of 610 patients enrolled by
July 2016, here we report the demographic and clinical
findings for the 556 symptomatic DM1 patients registered.
Methods
Design and setup
The TREAT-NMD Alliance is the result of a EU-funded
network of excellence with the remit of ‘‘reshaping the
research environment’’ in the neuromuscular field [17]. The
dataset collected within the registry includes all mandatory
and highly encouraged items agreed at the 2009 TREAT-
NMD and Marigold Foundation workshop held in Naarden
[18] (Table 1, full questionnaire available in supplemen-
tary material).
The UK Myotonic Dystrophy Patient Registry allows the
patient to initiate registration and provide the majority of the
information themselves online; while enabling them to
nominate a healthcare specialist (clinicians, nurse specialists
and physiotherapists) who, using a separate online account,
enters clinical and genetic details. This includes profes-
sionals from secondary healthcare only and does not include
general practitioners (GPs). This bespoke system allows the
healthcare professional to amend any inconsistencies in the
patient data, while providing the necessary clinical and
genetic details. This has been tested through a compliance
check performed on a random sample of 26 patient records
(Newcastle 8, Oxford 10, London 8) which showed a high
level of consistency between patient and clinician data
across three of the patient-reported symptoms (ambulatory
status 100%, dysphagia 100% and myotonia 84%).
Participants are encouraged to update details annually
allowing for the collection of longitudinal data. Informed
consent is provided online and allows for future contact to
be made, data provided to be used in research, and for the
additional data to be entered by a nominated professional.
The registry has received full ethical (Newcastle and North
Tyneside 1 11/NE/0179) approvals for conducting these
activities in the UK. The operation and maintenance of the
registry is carried out by a part-time curator at an annual
budget of approximately £15,000. It is governed by a
steering committee comprising multiple stakeholder groups
who adhere to Terms of Reference and Standard Operating
Procedures (available in supplementary material, details of
the committee are available on the registry website http://
www.dm-registry.org/uk).
Engagement and participation are known challenges in
this population [6, 22]. Therefore, recruitment has involved
a number of channels including working closely with
patient support and advocacy groups MDSG and MDUK.
In addition to distributing leaflets and newsletters, the
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regsitry engaged with molecular genetic diagnostic labo-
ratories diagnosing the condition and encoraged them to
include a statement about the registry on all positive
diagnostic reports.
Data cleaning and analysis
The completeness of both patient reported and profes-
sional-reported data varies, leading to different denomi-
nators in the calculations of percentages, which is clearly
stated in the results. Where more than one-time point is
available for any data item the most recent complete entry
has been used. A positive genetic diagnosis was considered
when the genetic report states that there is a CTG triplet
repeat expansion in the affected range at the DM1 locus.
Where a genetic diagnosis was not available the clinical or
patient self-report diagnosis has been taken into account.
Age of onset has been determined based upon the age
provided by the treating clinician and was classified into
five clinical forms, as recently proposed by Dogan et al.
[8]: (1) congenital form, onset from birth to 1 month; (2)
infantile form, onset from 1 month to 10 years; (3) juvenile
form, onset at 11–20 years; (4) adult form, onset at
21–40 years; and (5) late adult form, onset after the age of
40 years.
Statistical methods
Statistics have been carried out using IBM SPSS statistics
22. Correlation between two ordinal variables (e.g. severity
of symptoms) has been calculated using Spearman’s q.
Chi-square test and if appropriate Fisher’s exact test were
applied in categorical variables to determine statistical
significance. p values less than 0.05 were considered to be
statistically significant.
Results
A total of 610 patients registered in the UK Myotonic
Dystrophy Patient Registry between May 2012 and July
2016. A steady increase in registrants has been observed
with the largest growth in numbers seen when the registry
launched. On average 13 patients registered each month.
Sixty-seven healthcare professionals (clinicians, specialist
nurses and physiotherapists) have engaged and agreed to
contribute data to the registry (Fig. 1). Of all 610 patients,
556 reported DM1 with symptoms, 4 were asymptomatic,
14 reported DM2, and 36 had yet to receive a confirmed
diagnosis (Fig. 2). The following analysis included only
the symptomatic DM1 patients.
Patient demographics
A positive family history of the condition was reported by
89.1% (475/533) of patients although the detail of the
family relationship between affected persons was not col-
lected. Caucasian ethnic origin was reported by 97.3%
(532/547) of registrants, Asian by 0.009% (5/547), Black
African by 0.002% (1/547) and mixed by 0.02% (9/547). A
wide geographical distribution was seen with some clus-
tering around the large neuromuscular centres in New-
castle, Oxford, and London (Fig. 1). An even distribution
was seen between genders (women 51.1% (284/556), men
48.9% (272/556)) and a broad range of ages was present
from 8 months to 78 years (mean 41.1, standard deviation
(SD) ± 16.5) with the largest proportion, 63.8% (355/556)
between 30 and 59 years (Fig. 3). The age of onset was
available for 32.7% (182/556) of all patients and ranged
from birth to 68 years (mean 25.6, SD ±15.9), with the
largest proportion having adult onset (Table 2).
Symptoms and treatments
The most commonly reported symptoms in the registry
were fatigue/daytime sleepiness and myotonia, reported by
79.1 and 77.9% of patients, respectively (Table 2). These
symptoms were most often described as mild [fatigue 65%
(281/432); myotonia 74.9% (316/422)] and occurred across
all ages (Table 2). The correlation between myotonia and
fatigue was statistically significant (q = 0.461, p\ 0.001),
with relatively more patients having mild fatigue among
the patients with mild myotonia, and relatively more
patients having severe fatigue among the patients with
severe myotonia (Fig. 4). Similarly, there was a significant
correlation between myotonia and ambulatory status
(q = 0.337, p\ 0.001). Dysphagia occurred significantly
more frequently in patients with myotonia (55.3%,
223/403) compared to patients without myotonia (21.9%,
Table 1 Data items collected in the UK Muscular Dystrophy Patient
Registry, defined as patient or professional reported
Patient-reported data items Professional-reported data items
Demographics Age of onset
Family history Genetic confirmation (date,
laboratory, method, repeat number)
Ethnic origin Medication
Ambulatory status Heart condition (including cardiac
implant)
Wheelchair use Electrocardiogram
Myotonia (including
medication)
Ventilation
Fatigue/daytime sleepiness
(including medication)
Forced vital capacity (%)
Dysphagia Gastric tube
Pregnancy Cataract
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25/114, p\ 0.001, Fig. 4). No correlation existed between
fatigue and ambulatory status (q = 0.231).
A treatment with modafinil was given in 18.5% (80/432)
of patients with fatigue and 7.4% (32/432) used non-in-
vasive ventilation. Medication to help manage myotonia
was reported by 6.4% (27/422) of patients with myotonia,
with the most common medication mexiletine reported in
40.7% (11/27). Dysphagia was reported in 48.2% of
patients (Table 2), but only 2 patients with dysphagia used
a gastric tube for feeding.
The majority of patients, 65% (356/548), were ambulant
not using any assistive device to walk, 31.8% (174/548)
required some assistance, and 3.3% (18/548) were non-
ambulant. Of the patients needing some assistance,
wheelchair use was reported by 56% (94/168) of patients,
including 95.7% (90/94) of them using a wheelchair part-
time and 4.3% (4/94) using a wheelchair most of the time.
The age at which wheelchair use began ranged from less
than 1 to 72.4 years (mean 34.6, SD ±21.6). Among the
wheelchair users 22.8% (32/129) started before the age of
10 years and 56.6% (73/129) started to use a wheelchair
between 30 and 59 years.
Cardiac and pulmonary function
A routine electrocardiogram was reported for 33.8% (188/
556) and a heart condition (arrhythmia or conduction
block) was reported in 48.2% of patients (Table 2). The
age at diagnosis of heart condition ranged from less than 1
to 76.4 years (mean 36.5 years, SD ±19.1), with 73.6%
(78/106) of patients showing an onset before the age of
50 years and 15.1% (16/106) having a heart condition
before the age of 18 years. A wheelchair was used in
Fig. 1 Map of patients and doctors of the UK Muscular Dystrophy
Patient Registry. Blue pins represent an individual patient and yellow
pins a doctor providing data
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27.4% (29/106) of patients with cardiac abnormalities
where information for both items was available. A cardiac
implant was carried by 36.1% (39/108) of patients with a
heart condition, of which a pacemaker was reported in
87.2% (34/39) and an implantable cardioverter defibrillator
(ICD) in 12.8% (5/39) of patients. Information about the
age at which cardiac implant was inserted was available for
82.1% (32/39) of patients, 56.3% (18/32) of which required
a cardiac implant before the age of 50 years, but no
pacemaker was inserted in patients under 18 years of age.
Regular and ongoing non-invasive ventilation was nee-
ded in 14.9% of patients (Table 2), 52.9% (18/34) of which
reported mild and 41.2% (14/34) severe fatigue. Of those
using non-invasive ventilation, 64.7% (22/34) required
some assistance when walking and 50% (17/34) used a
wheelchair at least part time. Patients using non-invasive
ventilation reported a heart condition significantly more
frequently (76.7%, 23/30) compared to patients without
non-invasive ventilation (43.2%, 83/192, p = 0.001).
Seventeen percent (6/35) of patients with ventilation were
under the age of 30 years and there was no one registered
with invasive ventilation. The age at which ventilation
began was not recorded. The results of pulmonary function
testing were reported in 25.9% (144/556) of patients, with
52.8% (76/144) being normal ([70% forced vital capacity
(FVC)), 14.6% (21/144) showed moderate (60–69% FVC),
13.9% (20/144) moderately severe (50–59% FVC) and
18.8% (27/144) severe (\50% FVC) restriction. Of those
with severe restriction, 22.2% (6/27) of patients reported
using non-invasive ventilation, 80% (20/25) reported fati-
gue and 51.9% (14/27) used a wheelchair at least part time.
Of the patients with an FVC of greater than 70%, 5.3% (4/
76) were using a wheelchair part time compared to 42.4%
(28/66) of those with an FVC below 70%.
Cataracts
Information about cataract surgery was available for 40.1%
(223/556) of patients registered, of which 26% had catar-
acts removed (Table 2). Age of surgery was available for
84.2% (48/57) of these patients, 31.3% (15/48) of which
had surgery before the age of 40, 33.3% (16/48) reported
surgery between 40 and 49 years, and the remaining 35.4%
(17/48) had surgery after the age of 50 years.
Genetic diagnosis
The age of genetic diagnosis was available for 33.8% (188/
556) of patients and ranged from birth to 72 years (mean
36.4, SD ±15.7). The diagnosis of a large proportion of
patients, 65.4% (123/188), took place between 20 and
49 years. There was a notable age gap between the age of
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symptom onset and the age of genetic diagnosis; 14.9%
(20/134) participants received a genetic diagnosis within
12 months of symptoms onset and 13.4% (18/134) had the
genetic diagnosis before the age of onset. However, the
mean period from onset of symptoms to genetic diagnosis
was 9.1 years (SD ±11.1), for those with symptoms before
diagnosis the delay was 11.1 (SD ±10.4) years.
The CTG repeat length reported from standard diag-
nostic testing was only available for 11.3% (63/556) of
patients registered and ranged from 21.7 to 867 CTG
trinucleotide repeats (mean 364.3, SD ±266.1). Informa-
tion about age at onset was given for 81% (51/63) of those
with a repeat number available, 3.9% (2/51) of which were
categorised as congenital onset, 5.9% (3/51) as infantile,
35.3% (18/51) as juvenile, 31.4% (16/51) as adult, and
23.5% (12/51) as late adult onset. The two patients
reporting congenital onset had a reported CTG repeat
number of 450 and 700, those with infantile onset had
repeats between 700 and 833, juvenile onset patients had
129–867 repeats, adult onset 67–700, and repeat numbers
of patients with a late adult onset varied from 70 to 700.
The mean age at which the genetic testing was performed
was 13.5 years for patients with congenital onset,
28.1 years for infantile onset patients, 27.9 years for
patients with juvenile onset, 37.3 years for adult onset, and
52.2 years for patients with late adult onset.
The severity of symptoms (myotonia, fatigue, ambula-
tory status) was not correlated to the repeat size at the time
of diagnostic testing.
Gender differences
Myotonia was reported significantly more frequently by male
patients compared to females (p = 0.006) and men had sig-
nificantly higher occurrence of severe myotonia (p = 0.021).
Fatigue occurred almost as frequently in men as in women
(Table 2), but women reported this fatigue as severe signifi-
cantly more frequently (p = 0.028). Although not statistically
significant, more male patients reported dysphagia compared
to female DM1 patients (p = 0.21). There were more male
patients with mobility impairments (p = 0.84), wheelchair
use (p = 0.74), cardiac abnormalities (p = 0.42), and the
need of non-invasive ventilation (p = 0.56), whereas more
women had cataracts removed (p = 0.24), but these differ-
ences were not statistically significant.
Discussion
Successes and limitations
A diverse group of myotonic dystrophy patients have
registered, providing a cross-sectional snapshot of the
myotonic dystrophy population in the UK and the contri-
bution from healthcare professionals (clinicians, nurse
specialists and physiotherapists) across the country has
helped establish a virtual network of medical professionals
with an interest in myotonic dystrophy and research into
the condition [23]. The registry has successfully supported
recruitment into several academic research studies,
including the international trial OPTIMISTIC [24]
(NCT02118779), the national deep-phenotyping study
Pheno-DM1 (NCT02831504), and a pilot longitudinal
study at the University of Nottingham. In each case local
clinic-based recruitment was supplemented with nation-
wide registry recruitment, the latter accounting for 30–50%
of study participants. In addition, the registry is supporting
recruitment and feasibility for the first commercial clinical
trial in the UK (NCT02858908). It has also been utilised as
a research tool to help the National Institutes of Health
(USA) with ongoing research into myotonic dystrophy and
cancer, as well being part of an international effort to
collect additional information on common adverse events.
There are limitations to a patient initiated registry and
the design of this registry does include an element of self-
selection, therefore we cannot assume this cohort is fully
representative of the entire DM1 population in the UK. The
nature of the registry means that inclusion is biased
towards those that are able, willing, and interested to par-
ticipate in clinical research. It may be speculated that this
snapshot represents the less severe and more engaged
population of the DM1 population in the UK. However, it
could be argued that more severely affected patients may
engage more with research as there is a greater impact on
their daily lives. The reliability of the patient-reported
symptoms such as myotonia could also be questioned as
these terms may not be accurately understood by patients,
this may be a specific concern in DM1 considering the
cognitive impairment present in many. However, a limited
compliance check across three centres showed the relia-
bility of patient-reported data to be very promising, vali-
dating the move towards an increase in self-reported
outcomes. Furthermore, evidence suggests that patients
gain additional benefit from this level of engagement [25].
Clinical and genetic information is not available for
some patients; this is due to some delays in obtaining local
R&D approvals and the burden on the professional’s time.
Without full integration into the healthcare system or
provision of resources at a larger scale it may not be pos-
sible to capture complete genetic and clinical information
on all patients.
To improve the completeness of the data a larger pro-
portion of the data items could be completed by the patient
themselves, particularly relating to the age at onset and
questions regarding medications and ventilation. Having
more information about how many patients have tried a
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treatment but failed to tolerate it could help to improve
current best practice and warrant future investigation.
Clinical lessons and hypothesis generation
The registry has already helped to formulate hypothesis for
future studies which may lead to better understanding of
the condition. For example, the data presented support a
recent study indicating gender differences in DM1 [8].
Similar to this study, men had higher frequencies of severe
myotonia, mobility impairments, cardiac abnormalities,
and non-invasive ventilation, whereas women presented
more often with cataracts. Contrasting the results of Dogan
et al., the frequency of patients with dysphagia was slightly
higher in men than in women. We additionally found sig-
nificantly more severe fatigue among female DM1 patients,
which has not been described before. Although the symp-
toms in Dogan et al. were professional reported [8], many
of the gender differences were confirmed by our patient-
reported data in an independent population.
The most prevalent symptom described in the registry is
fatigue and excessive daytime sleepiness, known to also be
one of the most disabling leading to disability, unem-
ployment, family breakdown, and reduced quality of life
[26, 27]. Clinical reports and small studies suggest that
stimulating drugs such as modafinil may have a profound,
positive effect on excessive daytime sleepiness and quality
of life in DM1 patients [6, 22, 26]. However, after review
by the European Medicines Agency it was recommended
that due to lack of evidence [28] its use in myotonic dys-
trophy should be ceased. However, the unmet medical need
for treatment for fatigue remains strong and potentially
new molecules like pitolisant or other stimulant drugs [29],
may offer room for future trials seeking innovative solu-
tions for this prevalent symptom.
A correlation between dysphagia and myotonia has been
observed in the registry data, with dysphagia occurring
more frequently in patients who also report myotonia. This
positive correlation is also seen between myotonia and
mobility impairment. This is contradictory to the authors’
clinical impression that dysphagia is associated with mus-
cle weakness and is negatively correlated with myotonia.
Further clinical investigation may allow us to understand
these findings as they could impact care and treatment.
The data presented suggest that there is a significant
delay between symptom onset and genetic diagnosis [30].
This has been shown in other cohorts and suggests a need
to adopt better guidelines for the identification and diag-
nosis of DM1. There is rapid progress in the development
of new targeted treatments such as antisense oligonu-
cleotide therapies [14–16] and while these studies are
treated with appropriate caution, they highlight the need for
detailed genetic information in order for this community to
be not only ‘‘trial-ready’’ but also ‘‘treatment-ready’’.
Furthermore, delays in diagnosis prevent the best care
being provided to patients, such as existing approaches for
monitoring cardiac function and symptomatic treatments
for fatigue and myotonia. Genetic testing for DM1 by
Southern blot analysis of restriction digested genomic was
introduced into the UK in the early 1990s shortly after the
identification of the gene in 1992 [9–11]. A move was
made to triplet-primed PCR after this method was descri-
bed in 1996 [31]. Our data do not show a reduction of the
diagnostic gap in the last 20 years. This suggests that the
delay in genetic diagnosis is not due to availability of a
genetic test but to other factors. Consideration should be
given to assessing the reasons for the delay and the impact
this has on patient care and quality of life.
Our data regarding diagnosis could be improved with
better characterisation of age of onset and inclusion of
presenting symptom. This could help better understand if
certain symptoms such as bowel dysfunction (information
about which is not currently collected), cataracts, or
excessive daytime sleepiness may not be picked up as
quickly as muscle weakness or grip myotonia as suggested
by previous studies [32, 33]. As most diagnostic labora-
tories in the UK use the repeat-primed PCR assay, CTG
repeat lengths are not part of the diagnostic report, there-
fore these data are not readily available for most DM1
patients in the UK. This limits interpretation of genotype–
phenotype correlations, the value of this should be con-
sidered by health care providers considering the potential
added value in prognosis and standards of care.
Future considerations
The registry allows self-reported outcomes to be collected
from a large cohort of patients with direct and ongoing
access. The results shown here may inform the design of
future academic studies into the pathophysiology of the
condition and provide relevant information for clinical
trials. The collection of longitudinal data over time will
provide an additional resource when assessing the pro-
gression of the condition.
The common TREAT-NMD dataset is shared by at least
19 registries across 17 different countries (Argentina,
Australia, Bulgaria, Canada, China, Czech Republic,
Egypt, France, Germany, Italy, Japan, New Zealand,
Poland, Serbia, Spain, UK and US). Ideally, all registries
would be linked centrally by this common dataset allowing
data to be shared across the research community. The
TREAT-NMD Alliance has successfully established a
global network of national registries for Duchenne mus-
cular dystrophy and spinal muscular atrophy [34, 35] and
continues to play an active and important role in coordi-
nating neuromuscular registries globally. The registry is
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aiming to be part of any future collaborative efforts by
TREAT-NMD.
Increased harmonisation and collaboration not only
between registries, but also across resources could enable
communication between different health care systems in a
sensitive and secure manner. This kind of collaboration and
data sharing is key to understanding the natural history of
these complex and rare diseases and there are number of
initiatives in Europe currently looking at ways to achieve
this, for example RD-Connect (http://www.rd-connect.eu)
[17, 36].
The UK Myotonic Dystrophy Patient Registry is an
example of a novel, online-based, cost-effective, and
patient-driven registry. Its success can be measured by its
continuous growth and utilisation. Although primarily
designed to accelerate and facilitate trial recruitment and
planning the registry has also provided and interesting and
important data characterising the DM1 patient community
in the UK.
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